Cargando…

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic bene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Hersey, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489773/ https://www.ncbi.nlm.nih.gov/pubmed/23189245 http://dx.doi.org/10.4161/onci.19865

Ejemplares similares

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
por: Quek, Camelia, et al.
Publicado: (2021)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies
por: Chen, Lei L., et al.
Publicado: (2012)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
por: Todaro, Matilde, et al.
Publicado: (2013)

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
por: Janji, Bassam, et al.
Publicado: (2021)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression
por: Ho, Ping-Chih, et al.
Publicado: (2014)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
por: Rossig, Claudia
Publicado: (2012)

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide
por: Malvicini, Mariana, et al.
Publicado: (2012)

Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model
por: Lim, Joanne YH, et al.
Publicado: (2014)

Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15
por: Müller, Dafne
Publicado: (2012)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Antagonizing the innate pattern recognition receptor CD204 to improve dendritic cell-targeted cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2012)

Combining cellular and gene therapy approaches for treatment of intracranial tumors
por: Hickey, Michelle J, et al.
Publicado: (2013)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e8purde0bo9dqbf0rfl8r1i923